Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

Completed · Phase 3 · Has a placebo group

Conditions studied: Hereditary Angioedema, HAE

In brief

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

Key facts

Study ID
NCT03485911
Run by
BioCryst Pharmaceuticals
People needed
121
Starts
2018-02-06
Expected to finish
2022-04-06
Last updated by the study team
2023-06-26

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.